If you’re tracking the highest-efficacy weight-loss drugs still in development, retatrutide and CagriSema are the two names that matter most, and retatrutide currently holds…

CagriSema takes Wegovy’s active ingredient and adds a second drug to it, and the result is more weight loss, though at the cost of…

There’s an important catch to comparing orforglipron and Rybelsus: they’re not really competing for the same job. Orforglipron (Foundayo) is an oral pill approved…

The core difference between retatrutide and Mounjaro comes down to how many hormone targets each hits: retatrutide activates three receptors, while Mounjaro (tirzepatide) activates…

The newest weight-loss drugs work by hitting more hormone targets than GLP-1 alone, and the results suggest that more targets can mean more weight…

Amylin is emerging as the next major target in weight-loss medicine, offering a different mechanism than GLP-1 with a key advantage: gentler side effects….

The era of the weight-loss pill has arrived, and three names lead the next wave: orforglipron (already approved), amycretin, and VK2735 (both investigational). All…

Retatrutide has produced some of the largest weight loss of any drug in development, reaching roughly 24% in mid-stage trials and climbing toward 30%…

Retatrutide’s side effects are mostly the familiar gastrointestinal ones seen across weight-loss drugs, but it has one distinctive addition: a skin-tingling sensation called dysesthesia…